●亚振家居股份有限公司（以下简称"公司"）股票于2025年5月6日、7日、8日连续三个交易日内日收盘 价格涨幅偏离值累计达到12%，属于股票交易异常波动。 ●生产经营风险。公司2024年度经审计的扣除非经常性损益后的净利润为负值，且扣除与主营业务无关 的业务收入和不具备商业实质的收入后的营业收入低于3亿元，触及《上海证券交易所股票上市规则》 第9.3.2条第一款第（一）项规定，公司股票于2025年5月6日起实施退市风险警示。公司2025年第一季度 营业总收入为4,067.57万元（未审计），归属于上市公司股东的净利润为-2,131.38万元，归属于上市公 司股东的扣除非经常性损益的净利润为-2,047.67万元（未审计）。 ●经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，除上述控制权变更事项外，确 认不存在应披露而未披露的重大事项和风险事项。 登录新浪财经APP 搜索【信披】查看更多考评等级 一、股票交易异常波动的具体情况 证券代码：603389 证券简称：*ST亚振 公告编号：2025-021 亚振家居股份有限公司 股票交易异常波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任 ...

航天南湖发布股票交易异常波动公告，经公司自查并向控股股东及实际控制人核实，不存在应披露而未 披露的重大信息。公司股价短期波动幅度较大，敬请广大投资者注意二级市场交易风险，理性决策，审 慎投资。 ...

4连板精进电动公告，公司股票交易连续10个交易日内收盘价格涨幅偏离值累计超过100%，属于股票交 易严重异常波动。经自查并向控股股东、实际控制人核实，不存在应披露而未披露的重大信息。公司年 度及季度仍处于亏损状态，敬请广大投资者注意二级市场交易风险，避免跟风炒作，理性决策，审慎投 资。 ...

Group 1 - The company will participate in the "2024 Annual Performance Briefing and Investor Reception Day" on May 13, 2025, to enhance communication with investors regarding its annual report and other key topics [1] - The company has received marketing authorization from the Therapeutic Goods Administration (TGA) in Australia for its injectable drug Bivalirudin, which is indicated as an anticoagulant for high-risk acute coronary syndrome patients [3][4] - The injectable Bivalirudin has previously received approvals from various regulatory bodies, including the FDA in the United States and the Saudi Arabian SFDA [5] Group 2 - The company's stock has experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 12% over two consecutive trading days [9] - The company has confirmed that there are no undisclosed significant matters that could affect its stock price, and it has conducted a thorough review of its recent trading activity [10][11] - The company has been placed under a delisting risk warning due to negative financial results, with the lowest of its audited profit total, net profit, and net profit after non-recurring gains and losses being negative, and revenue below 300 million [12]

Core Viewpoint - Hubei Jiuyou Investment Co., Ltd. has experienced significant stock price fluctuations, with a cumulative decline of over 12% in three consecutive trading days, raising concerns about potential delisting due to financial issues [2][3][9]. Group 1: Stock Trading Anomalies - The company's stock price fell significantly on April 25, April 28, and April 29, 2025, with a cumulative price deviation of over 12%, indicating abnormal trading activity [2][3]. - On April 29, 2025, the stock closed at 0.96 yuan, marking the first time it fell below 1 yuan, which triggers a risk warning regarding potential delisting [2][9]. Group 2: Financial Audit and Reporting - The auditing firm Zhongxing Caiguanghua issued an audit report with a disclaimer of opinion for the company's 2024 financial statements, indicating the company has reached a financial delisting condition [2][9][11]. - The company has been notified by the Shanghai Stock Exchange regarding the potential termination of its stock listing due to the audit findings [11][15]. Group 3: Company Operations and Management - Despite the stock price fluctuations, the company reported that its production and operational activities remain normal, with no significant changes in its main business [4]. - The company confirmed that there are no undisclosed significant events that could impact stock prices, including major asset restructuring or debt reorganization [5][7]. Group 4: Regulatory Compliance and Future Actions - The company is required to disclose risks associated with the potential delisting and must ensure compliance with relevant regulations during this process [12][13]. - The company must appoint a sponsor to facilitate the transition to the National Equities Exchange and Quotations system within 45 trading days after delisting [12][16].

Core Viewpoint - Zhangjiagang Free Trade Zone Technology (Group) Co., Ltd. has experienced significant stock price fluctuations, with a cumulative closing price deviation exceeding 20% over three consecutive trading days, prompting a warning to investors about market risks [2][6]. Company Operating Conditions - For the year 2024, the company reported a revenue of 899.88 million yuan, a decrease of 39.96% year-on-year, and a net profit attributable to shareholders of 209.77 million yuan, down 16.83% year-on-year, primarily due to a decline in the average storage capacity utilization rate in liquid chemical warehousing [2]. - As of the date of the announcement, the company's production and operational activities are normal, with no significant changes in its main business, market environment, or industry policies [2]. Stock Price Fluctuation Information - The company's stock closed at 5.04 yuan on April 21, 2025, with a daily increase of 10.04% [2][6]. - The latest price-to-earnings (P/E) ratio for the company is 28.83, which is higher than the industry average P/E ratio of 21.79 [6]. Major Information Disclosure - The company has confirmed that there are no undisclosed significant matters that could affect stock price fluctuations, including major asset restructuring or significant contracts [4][7]. - There have been no media reports or market rumors that require clarification or response from the company [5].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002836 证券简称：新宏泽 公告编号：2025-008 广东新宏泽包装股份有限公司股票交易异常波动公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股票交易异常波动的情况介绍 广东新宏泽包装股份有限公司（证券简称：新宏泽；证券代码：002836，以下简称"公司"或"本公司"） 股票于2025年4月17日、2025年4月18日连续2个交易日收盘价格涨幅偏离值累计达到20%，根据《深圳 证券交易所交易规则》的相关规定，属于股票交易异常波动的情况。 3、公司经营情况及内外部经营环境未发生重大变化。 4、经公司自查和问询控股股东和实际控制人，公司、控股股东和实际控制人不存在关于公司的应披露 而未披露的重大事项，或处于筹划阶段的重大事项；公司控股股东和实际控制人在股票交易异常波动期 间不存在买卖公司股票的情形。 二、公司关注并核实的相关情况说明 针对公司股票交易异常波动，公司对有关事项进行了核查，并对控股股东及实际控制人就相关事项进行 了核实，现就有关情况说明如下： 1、公司前期所披露的信息不存在需 ...

一、股票交易异常波动的具体情况 公司股票交易在2025年4月16日、4月17日、4月18日连续3个交易日内日收盘价格跌幅偏离值累计达到 12%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动的情形。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 青海春天药用资源科技股份有限公司（以下简称"公司"）股票交易在2025年4月16日、4月17日、4月 18日连续3个交易日内日收盘价格跌幅偏离值累计达到12%，属于股票交易异常波动。 ● 经公司自查及向公司控股股东、实际控制人发函核实、确认，截至本公告披露日，除公司已披露事项 外，不存在其它应披露而未披露的重大事项。 ● 公司披露了《关于2024年年度财务报表审计阶段性说明的公告》，根据年审会计师审计阶段性说明及 《上海证券交易所股票上市规则》9.3.2条相关规定，公司2024年年度报告披露后可能会被实施退市风险 警示。 ● 请广大投资者理性投资，注意股票二级市场的交易风险。 经核查，公司实际控制人 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688602 证券简称：康鹏科技 公告编号：2025-032 上海康鹏科技股份有限公司股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 上海康鹏科技股份有限公司（以下简称"公司"或"康鹏科技"）股票连续两个交易日（2025年4月17 日、4月18日）内日收盘价格涨幅偏离值累计超过30%，根据《上海证券交易所交易规则》《上海证券 交易所科创板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动情形。 ● 经公司自查，并发函问询了公司控股股东、实际控制人，截至2025年4月18日，公司不存在应披露而 未披露的重大信息。 ● 截至2025年4月18日，公司收盘价为9.66元/股，根据中证指数有限公司发布的数据，公司最新市盈率 为44.52倍；公司所处的化学原料及化学制品制造业最近一个月平均滚动市盈率为22.72倍，公司市盈率 高于行业市盈率水平。 一、股票交易异常波动的具体情况 公司股票连续两个交易日（2025年4月17日、 ...